Revenue for the quarter increased by 5.3% from the same quarter last year to ₹1,811 crore. The figure is below the CNBC-TV18 poll estimate of ₹1,995.8 crore.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter increased by 21.7% from the year-ago period to ₹511 crore, which is also lower than the CNBC-TV18 poll projection of ₹558 crore.
EBITDA margin for the period stood at 28.2% from 24.4% last year and largely in-line with the poll projection of 28%.
Net profit for the period increased by 19% year-on-year to ₹279 crore. The CNBC-TV18 poll had projected the figure to be ₹297.9 crore.
Founder and CEO Satyanarayana Chava attributed the results to successful commercial supply for NCE programs, ramp-up of new launches and sustained leadership in the Anti-retroviral segment.
“The transformation of our portfolio is well underway, and momentum is building. We are making significant investments in novel technologies, scale and strengthening integrated capabilities offerings towards laying foundation for future growth,” he added.
For the quarter, Laurus Labs’ CDMO business saw revenue growth of 20% from last year to ₹589 crore, while its key generics business saw a 1% decline to ₹1,223 crore.
Within the generics business, the API business revenue grew by 13%, but the FDF business saw a 17% decline to ₹451 crore.
Shares of Laurus Labs are down 1% on Thursday after the results announcement at ₹1,095.5. The stock has remained flat through 2026, declining only 2%.
First Published: Apr 30, 2026 3:28 PM IST
